Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21659403 | 0.99 | HRH3 (0.68) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL6472573 | 0.89 | HRH3 (0.72) | HRH3KCNH2MAPTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL3581152 | 0.86 | HRH3 (0.69) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3585244 | 0.85 | HRH3 (0.71) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3579866 | 0.85 | HRH3 (0.63) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL13438043 | 0.85 | HRH3 (0.63) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3586381 | 0.84 | HRH3 (0.66) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3585275 | 0.84 | HRH3 (0.62) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3581097 | 0.83 | HRH3 (0.64) | HRH3KCNH2MAPTALDH1A1GAA | |
| SCHEMBL3580433 | 0.83 | HRH3 (0.66) | HRH3KCNH2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 352/4885MAPT 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.